PetVivo Sets Fiscal Third Quarter 2026 Conference Call for Monday, February 16, 2026 at 5:00 p.m. ET
MWN-AI** Summary
PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW), an innovative biomedical company specializing in medical devices and therapeutics for equines and companion animals, has announced that it will conduct a conference call on February 16, 2026, at 5:00 p.m. ET to discuss its financial performance for the fiscal third quarter ended December 31, 2025. Interested participants can access the call via a toll-free dial-in number (+1 719 359 4580) using the Conference ID: 85272254834 and Passcode: 737862. Additionally, a live webcast will be available, with a replay accessible afterward on the company's investor relations page.
PetVivo Holdings aims to revolutionize veterinary care by leveraging its proprietary technologies in the manufacturing and commercialization of medical devices intended for animal treatment. Notably, the company has developed products such as SPRYNG® with OsteoCushion® technology, which provides veterinarians with a method to manage joint-related afflictions in pets, and PrecisePRP®, an off-the-shelf platelet-rich plasma product for similar applications.
With a focus on accelerated revenue generation, PetVivo's business model allows it to bring veterinary medical devices to market more swiftly than traditional pharmaceuticals. The company holds a diverse patent portfolio and is committed to advancing biomaterial technologies that enhance veterinary care and facilitate timely interventions for pets.
CEO John Lai and the management team will discuss the quarter’s financial results and provide insights into future business plans during the call. As a forward-looking entity, PetVivo reminds investors that the information shared may contain forward-looking statements subject to risks and uncertainties, emphasizing the importance of staying informed through formal reports filed with the SEC.
MWN-AI** Analysis
PetVivo Holdings, Inc. (OTCQX: PETV) is poised to provide significant updates during its fiscal third-quarter conference call on February 16, 2026, at 5:00 p.m. ET. This call will offer insight into the company’s financial performance and operational developments through December 31, 2025, which is critical for investors monitoring the evolving landscape of the veterinary health market.
Given the company’s strategic emphasis on biomedical devices for companion animals, particularly the promising SPRYNG® product targeting joint ailments, PetVivo appears well-positioned for growth. With a portfolio backed by twelve patents and trade secrets and pioneering products like PrecisePRP®, the firm leverages human therapeutic advancements to create veterinary solutions, allowing for a faster route to market compared to pharmaceuticals. This innovation is essential in a sector where demand for effective treatments continues to rise.
Investors should be attentive to the revenue trends anticipated from these products, particularly following the recent expansion in their commercialization efforts. Any indications of increased adoption rates from veterinarians and pet owners during the call could signal strong future performance and yield potential upside in the share price.
Furthermore, the market outlook suggests a favorable environment for companies focusing on the intersection of human and animal health. As PetVivo continues to build its pipeline and refine its product offerings, analysts should evaluate the company’s capacity to scale operations efficiently. Monitoring projected timelines also remains crucial, as any delays could impact investor sentiment.
In summary, as PetVivo prepares for its conference call, stakeholders should assess the company’s financial health, updates on product sales, and future growth strategies. A comprehensive understanding from this call will allow for informed investment decisions, especially considering the accelerating trends in animal health and wellness.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MINNEAPOLIS, MN, US, Feb. 09, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., including its wholly-owned subsidiary Petvivo Animal Health, Inc. (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, will hold a conference call on Monday, February 16, 2026 at 5:00 p.m. Eastern time to discuss results for the fiscal third quarter ended December 31, 2025. The financial results will be issued in a press release prior to the call.
PetVivo management will host the presentation, followed by a question-and-answer period. The Fiscal Third Quarter 2026 conference call information is as follows:
Date: Monday, February 16, 2026
Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)
Toll-free dial-in number: +1 719 359 4580
Conference ID: 85272254834
Passcode: 737862
Webcast (live and replay): Click here
A replay of the webcast will be available through the same link following the conference call.
The conference call webcast replay will also be available via a link in the Investors section of the company’s website at petvivo.com/investors.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP®, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ**
How does PetVivo Holdings Inc. plan to expand its product offerings related to the PetVivo Holdings Inc. Warrant PETVW in the coming fiscal quarters?
What are the key financial metrics that investors should focus on during the upcoming conference call regarding PetVivo Holdings Inc. Warrant PETVW?
Can you provide updates on the regulatory status and market performance of SPRYNG® as it relates to the PetVivo Holdings Inc. Warrant PETVW?
How are current industry trends in veterinary medicine impacting the valuation of PetVivo Holdings Inc. Warrant PETVW and its future growth prospects?
**MWN-AI FAQ is based on asking OpenAI questions about PetVivo Holdings Inc. Warrant (OTC: PETVW).
NASDAQ: PETVW
PETVW Trading
0.07% G/L:
$0.0344 Last:
5,000 Volume:
$0.034375 Open:
